CTIS2023-503371-25-00招募中1 期
Does the Glucagon-like Peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol intake in patients with Alcohol Use Disorder and comorbid obesity?
Psykiatrisk Center Kobenhavn0 个研究点目标入组 108 人开始时间: 2023年3月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Informed oral and written consent, Diagnosed with alcohol dependence according to the criteria of the International Classification of Diseases 10 (ICD-10), and diagnosed with alcohol use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), Alcohol use disorder identification test (AUDIT) score >15, Body mass index (BMI) above or equal to 30 kg/m2, Age 18 - 70 years (both included), Heavy alcohol drinking defined as more than 6 days with alcohol consumption over 4 units (48 g alcohol) for women and 5 units (60 g alcohol) for men during a consecutive 30-day period, within 40 days prior to baseline evaluation, measured by the TLFB method. The 30-day period will be the 30 days with the biggest alcohol intake (most heavy drinking days and the largest amount of total alcohol) out of the 40 days.
排除标准
- •Severe psychiatric disease, defined as a diagnosis of schizophrenia, paranoid psychosis, bipolar disorder or mental retardation, Impaired pancreatic function (any history of acute or chronic pancreatitis and/or amylase > 2 times upper limit), Former medullary thyroid carcinoma (MTC) and/or family history with MTC and/or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), Cardiac problems defined as decompensated heart failure (NYHA class III or IV), unstable angina pec-toris and/or myocardial infarction within the last 12 months, Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >110 mmHg), Concomitant pharmacotherapy against alcohol use disorder i.e. disulfiram, naltrexone, acamprosate, or nalmefene, since the first of the 30 drinking days registered for inclusion at the TLFB-schedule., Receiving any investigational drug within the last three months, Use of weight-lowering pharmacotherapy within the preceding 3 months, Any other active substance use defined as a DUDIT-score >1 (except nicotine), Hypersensitivity to the active substance or any of the excipients, Only for patients undergoing brain scans: Contraindications for undergoing an MRI scan (magnetic implants, pacemaker, claustro-phobia, etc.), A history of delirium tremens or alcohol withdrawal seizures, Unable to speak and/or understand Danish, Any condition that the investigator feels would interfere with trial participation, No serious withdrawal symptoms at inclusion (a score higher than 9 on the Clinical Institute With-drawal Assessment of Alcohol Scale, Revised (CIWA-Ar)) at baseline examinations, Present or former neurological disease, including traumatic brain injury, Type 1 diabetes, type 2 diabetes in poor glycaemic control (defined as HbA1c =48 mmol/l or fasting plasma glucose above 7.0 mmol/l at inclusion), Females of childbearing potential who are pregnant, breast-feeding or have the intention of becoming pregnant within the next 9 months (26 weeks plus three months after discontinuation of semaglutide), or are not using contraceptives (during the whole study period) considered as highly effective (combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) intrauterine device – IUD, IUS, bilateral tubal occlusion, vasectomised partner, sexual abstinence), Pregnancy (serum human chorionic gonadotropin (hCG) > 3 U/L at inclusion), Impaired hepatic function (liver transaminases >3 times the upper limit), Impaired renal function (eGFR < 50 ml/min and/or plasma creatinine >150 µmol/l)
研究者
相似试验
进行中（未招募）
1 期
Does stimulation of the receptor for Glucagon-like Peptide 1 (GLP-1) reduce alcohol intake in patients with alcohol dependence?Alcohol dependenceEUCTR2016-003343-11-DKPsychiatric Centre Copenhagen169
尚未招募
2 期
SemaPsychiatrySchizophrenia2024-518746-24-00Psykiatrisk Center Kobenhavn104
撤回
2 期
The physiology of glucagon-like peptide-1 receptor expression in patients with endogenous hyperinsulinism: correlation with histopathologyCongenital hyperinsulinism1001469910018424CHINL-OMON42359ucleaire geneeskunde en radiologie10
进行中（未招募）
不适用
imaging of insulin producing cells in patients with genetic insulin overproductioCongenital hyperinsulinismMedDRA version: 18.0Level: PTClassification code 10061211Term: HyperinsulinismSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-002692-18-NLEuropean Commission40
进行中（未招募）
1 期
A study to evaluate the effect of a licensed drug to lower blood glucose, liraglutide, on inflammation in patients with diabetic kidney disease.EUCTR2012-005482-12-IEniversity College Dublin